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Summary: Intercellular adhesion molecule-1 (ICAM-1), a raember of the immunoglobulin gene superfamily, is a
cytokine-inducible adhesion molecule, which plays a central role in leukocyte migration into sites of acute or
chronic inflammation. In this article we describe a sandwich immunoenzymometric method which allows rapid,
semiquantitative (in "enzyme immunoassay units", EU) identification of ICAM-1 on the surface of alveolar macro-
phages. We evaluated this method in two groups of patients with pulmonary sarcoidosis (n = 12) or bacterial
pneumonia (n = 11) and a group of healthy volunteers (n = 6), comparing the results with those obtained by
immunocytochemical staining. ICAM-1 expression on the sarcoid alveolar macrophages surface was significantly
elevated, s compared with control alveolar macrophages (0.76 EU ± 0.27 vs. 0.44 EU ± 0.12, p < 0.01). ICAM-
1 expression on the surface of alveolar macrophages from patients with pneumonia was not elevated (0.48 EU
± 0.35). Stimulation with tumour necrosis factor-α (TNF-a) or interferon-γ (100 kU/1) led to a significant induction
of ICAM-1 on the surface of control alveolar macrophages (0.76 EU ± 0.18, p < 0.005 for TNF-a, 0.64 EU ± 0.10,
p < 0.005 for interferon-γ), whereas alveolar macrophages from both patient groups did not respond to cytokines
even at high dosages. ICAM-1 expression on the surface of alveolar macrophages from patients with sarcoidosis
correlated with the spontanepus release of TNF-α by macrophages (R = 0.77, p < 0.05). To summarize, the evalu-
ation of ICAM-1 levels on the surface of cells harvested from the pulmonary c mpartment is a useful tool for
interpreting the mechanisms leading to leukocyte cc mulation and activation in inflarnmatory disorders of the lung.
Introduction (5, 6). Structurally, ICAM-1 is a member of the
T ^ 1t , „ . . t , / T ^ A A V T ix · ^ immunoglobulin supergene family with 5 immunoglob-Intercellular adhesion molecule-1 (ICAM- 1) is a cyto- , . . . , , . ,* ~ ., . , , ,, . . , ".-.. ,, . Λ . , . , ulm-hke domains (7). Considermg current knowledge onkme-inducible adhesion molecule expressed on a wide · ' . Τ Λ Α Λ^ Λ Λ - · ^
variety of cells at sites of inflammation (i, 2). It is the the ^nctloun of IC^M- du""g ^zmmMon, stud.es
principal receptor for the integrin lymphocyte fonction K^dm^ thePosslble role of ICAM-1 express,on on the
associated antigen-1 (3) aod mediales a n mfcer of ad- surface of alveolar macrophages in the pathogenesis of
hesion events among leukocytes and'between leukocytes inflammatory disorders of the lung are remarkably rare
and other cells types (l, 4). ICAM-11) plays a major role (8~ 10)· We therefore developed a rapid and reliable me-
in controlling leukocyte trafficking into inflamed organs thod for identification of ICAM-1 levels on the surface
of alveolar macrophages harvested by bronchoalveolar
-- lavage. Based on cell-physiological ELISA methods
i ') Abbreviations: ICAM-1 (Intercejlular Adhesion Molecule-i, (Π), we describe in this report an immunoenzymometric
· which a"ows *gamma (interferon-γ). quantitative and reproducible detection of ICAM-1 on
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Ihe surface of alveolar macrophages. We evaluated this
method in two groups of patients with pulmonary sar-
coidosis or bacterial pneumonia, comparing the results
with those obtained from alveolar macrophages of heal-
tliy volunteers. We examined both basal and stimulated
ICAM-1 expression following 16 hours of incubation
with interferon-γ or TNF-α. ICAM-1 expression in the
sarcoidosis group was compared with TNF-α concen-
tration in the supernatants of alveolar macrophages s an
established characteristic of macrophage activity (10).
Patients suffering from pulmonary sarcoidosis were
chosen because this disease provides an example of a
strongly compartmentalized inflammatory disorder with
accumulation of highly activated macrophages and lym-
phocytes in the lung (13—20). Patients with bacterial
pneumonia were chosen because this disease, in con-
trast, is characterized by neutrophil accumulation in the
pulmonary compartment.























































Human recombinant tumour necrosis factor-α and human recombi-
nant interferon-γ were obtained from Serva, Heidelberg, Germany.
Stock Solutions of cytokines were stored aliquoted at —80 °C. The
freeze-dried monoclonal mouse antibody against human ICAM-1
(clone 84H10) was purchased from Dianova, Hamburg, Germany.
The antibody was reconstituted with phosphate-buffered saline (0. l
mol/1, pH 7.2) containing l g/I bovine serum albumin (Serva, Hei-
delberg, Germany) and sodium azide (l g/l) to a final antibody
concentration of 0.1 g/l. This stock solution could be stored at 4 °C
for up to three months. Monoclonal antibodies against CD3, CD4,
and CD8 were purchased from Dianova, Hamburg, Germany and
Ortho Diagnostics, Beerse, Belgium, respectively. Peroxidase con-
jugated goat anti-mouse antibody was obtained from Sigma, Dei-
senhofen, Germany. Appropriate stock Solutions of these antibodies
in l g/l bovine serum albumin were stored at 4 °C and dissolved
in phosphate-buffered saline (0.1 mol/1, pH 7.2) for use in the
experiments. The neutralizing anti-TNF-α antibody was obtained
through H. Biermann, Bad Nauheim, Germany from British Bio-
technology and was kept aliquoted at -20 °C. 2,2'-Azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) diammonium salt (ABTS)
was purchased from Sigma. Reagents for immunocytochemical
staining were from Dako, Hamburg, Germany. All cell culture me-
dia and Supplements were obtained from Gibco, Eggenstein, Ger-
many.
Study popula t ion
The study population consisted of 12 consecutive, untreated
patients with active biopsy-proven sarcoidosis of the lung (radio-
logical type I: n = 9, type II: n = 3) and 11 untreated patients with
clinical and radiological signs of bacterial pneumonia. As controls,
six healthy volunteers were studied. The three groups were com-
parable with respect to Smoking habits, which have been shown lo
influence expression of adhesion molecules (21).
Ethical committee approval and individual informed consent were
obtained.
Clinical data and lavage cell characteristics are summarized in
tablel.
Bronchoalveolar lavage and cell Isolation
Bronchoalveolar lavage was performed using a flexible fiberscope
in the right middle lobe under Standard conditions (22). Lavage
volume was 200 ml with a ine n recovery of 84%, and was not
statistically diiferent in patients and controls. The fifst 20 ml ali-
quot of the lavage, which is known to be contaminated with bron^
chial secretions (23), was discarded and remaining portions were
pooled. After evaluation of total cell count on a haemocytometer
(Neubauer), lavage cell differentials were determined by Wright-
Giemsa staining of cytocentrifuge preparations (Cytospin II, Shan-
don). Cell viability was assessed nsirig trypan blue dye exclusion
(88.7% ± 6.6 for all cases). For microscopical differentiation of
lymphocyte subsets (CD3, CD4, CD8), fluorescein-conjug ted
monoclonal antibodies were used. Lavage cells were washed twice
using phosphate-buffered saline and resuspended at a viable al-
veolar macrophages concentration of 109/1 in M199 supplemented
with foetal calf serum (50 ml/l, Gibco), Z,-glutamine (2 mmol/1,
Gibco) and penicillin/streptomycin (l g/l, Gibco).
ICAM-l expression on the surface of alveolar
macrophages
ICAM-1 expression on the surface of alveolar macrophages was
determined using an immunoenzymometric assay teohnique.
Mononuclear lavage cells containing viable alveolap macroph' ges
at a density of 109/1 were seeded into 96-well flat bottom microtitre
plates (100 μΐ/well) for three hours (37 °C, 5% CO2) to allow the
macrophages to adhere. We chose this cell concentrations from the
linear portion of the cell number/absorbance curve. Non-adherent
cells were removed by gently washing three times with warm cell
culture medium. Serum-supplemented M199 (100 μΐ/well) with or
without 100 kU/1 interferon-γ or TNF-α was added. Incubation was
continued for 16 hours at 37 °C in a totaHyJhumidified atmosphere
containing 5% CO2. At the end of the inc bation time cells were
washed twice and fixed with 10 g/l paraformaldehyde (l h, 21 °C).
After washing the fixed cells t ree times with phosphate-buffered
saline (0.1 mol/1, pH 7.2) free birtding sites were blocked by adding
a 20 g/l solution of bovine serum albumin dil ted in phosphate-
buffered saline, 0. l mol/1 for l -houtit 37 °C. The blocking solution
was removed by Inversion of the microtitre plate and gently tap-
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ping it on a soft paper tissue. A total of 100 μΐ of the monoclonal
mousc anti-ICAM-1 antibody in an antigen-saturating concen-
tration (l : 1000, containing l g/l bovine serum albumin) was ad-
ded to each well for two hours at 37 °C. At the end of the two
hours, plates wcre washed three times and 100 μΐ of the developing
antibody was added (peroxidase conjugated goat anti-mouse anti-
body, l : 1000, containing l g/l bovine serum albumin). After incu-
bating the plates for l hour at 37 °C, the enzyme conjugate was
removed and plates were washed four times with phosphate-buff-
ered saline. Finally ABTS (l g/l) and hydrogen peroxide (2.8 μΐ
300 g/kg H2O2 per 10 ml) in 0.1 mol/1 sodium acetate, (pH 4.2)
was added. The colour was allowed to develop for 120 minutes
and plates were read with a microplate reader (Behring EL 311) at
405 nm. Appropriate controls were included in each assay. These
include omission of the primary antibody and/or the developing
antibody and/or the Substrate or the cells. Non-specific binding of
the primary monoclonal mouse antibody to alveolar macrophages
was quantified using mouse IgGi instead of the anti-ICAM-1 anti-
body. Results are expressed s enzymeimmunoassay units (EU)
from quadruplicate wells calculated s the difference of ab-
sorbances (ΔΑ405 nm) measured in the wells with added anti-ICAM-
1 antibody and in the control wells with added mouse IgGj. One
EU is defined s A^snm = A405nm anti-ICAM-1 antibody —
A405nm mouse IgG^ intraassav Variation 9.7%. The number of ad-
herent cells at the end of each experiment was not different in
patient samples and controls s quantified by crystal violet staining.
Cell viability after 16 hours of Stimulation was determined ran-
domly in separate experiments using a colorimetric assay according
to Mosmann (24).
l inmunocytochemical staining
For immunocytochemical staining of ICAM-1 cytocentrifuge prep-
arations of the lavage cells were dried at room temperature,
wrapped in aluminium foil and stored at —20 °C until use.
Immunocytochemical staining was performed using the alkaline
phosphatase monoclonal mouse anti-alkaline phosphatase complex
s described (25). Briefly, frozen slides were warmed to room tem-
perature before unwrapping, After fixing the cells for 2 min with
pure acetone and washing with Tris^buffered saline (pH 7.6), slides
were incubated for 30 min at 21 °C with 200 μΐ of the monoclonal
anti-ICAM-1 antibody (l : 25) in a humidified chamber.
The primary antibody was removed and slides were washed twice
before adding 200 μί of a rabbit anti-mouse antibody for 30 min.
After two washings with Tris-buffered saline slides were incubated
with 200 μΐ of a l : 50 dilution of the alkaline phosphatase mono-
clonal mouse anti-alkaline phosphatase complex.
The alkaline phosphatase product was visualized using a naphthol
AS-MX phosphate fast red solution (Sigma, Deisenhofen, Ger-
many), containing l mol/1 levamjsole to inhibit endogenous alka-
line phosphatase. Finally, slides were coutterstained with haem-
alaun (20 min) and blued under running tap water (10 min).
Tumour necrosis factor-α bioassay
For determination of TNF-α, alveolar macrophages from patients
with sarcoidosis and healthy volunteers were cultured in 96-well
microtitre plates s described above. After removing non-adherent
ceils 100 μΐ fresh Ml99 supplemented with 50 ml/l foetal calf
seruni was added to each well. Supernatants were removed from
at least 6 wells after 60 min (37 °C). Samples from triplicate wells
were pooled into one tube and immediately frozen at -20 °C.
TNF-α was measured using a L929 fibroblast lytic assay s prc-
viously described (26). Briefly, L929 cells (60000/well) were cul-
tured in 96-well flat'bottom microtitre plates (Nunc) containing
threefoid serial dilutions of conditioned supernatant of sarcoid al-
veolar macrophages, in the presence of actinomycin D (l mg/J, to-
tal assay v lume: 200 μΐ/well). After 20 hours of incubation, the
renoaining L929 cells were stained with crystal! violet. The TNF-a
concentration of the triplicate samples was quantified by compar-
ing the results with the linear portion of a Standard curve, pbtained
with human recombinant TNF-a (6.6 X l O6 kU/g). The specificity
of this bioassay was tested by neutralizing peak samples with a
goat anti-human-TNF-α antibody (0.1-100 mg/1).
Statistics
Non-parametric statistics were used throughout the study. The Wil-
coxon signed rank test was used for paired samples and the Mann-
Whitney Uztest for independent samples. Correlations were madc
with the Spearman rank correlation. The median was used s a
marker of central tendency. Differences were considered statisti-
cally significant per p < 0.05 (27).
Results
Total and differential cell count
Table l shows the lavage cell characteristics. As ex-
pected, the total number of recovered bronchoalveolar
lavage cells was increased in both patient groups. The
percentage of lymphocytes in the sarcoidosis group was
significantly increased, compared with healthy controls
(p < 0.005). In patients with pneumonia, neutrophils but
not lymphocytes were significantly increased in bron-
choalveolar lavage.
Expression of ICAM-1 on alveolar
macrophages
Using the immunoenzymometric assay, ICAM-1 ex-
pression on the surface of alveolar macrophages was de-
Control Pneumonia Sarcoidosis
Fig. l Bas l (dark columns) and interferon-γ induced (100 kU/1,
white columns) ICAM-1 expression on the surface of alveolar ma-
crophages from patients and controls. Mean ± SD.
* = p < 0.01 versus basal expression on the surface of control
alveolar macrophages.
** = p < 0.05 versus basal expression on the surface of control
alveolar raacrophages.
Control (n = 6);
Pneumonia (n = 11),
Sarcoidosis (n = 12).
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tected in all cases (flg. 1). Specific antibody binding was
determined for each patient/control by subtracting non-
specific binding of mouse IgG, to alveolar macrophages
(fig. 2). In all cases absorbance due to non-specific bind-
ing did not exceed 10% of maximum absorbance ob-
tained after addition of the specific anti-IC AM-1 anti-
body. We found significantly elevated ICAM-1 ex-
pression on the surface of sarcoid alveolar macrophages,
compared with those of healthy controls (0.76 EU
±0.27 vs. 0.44 EU ±0.12, p < 0.01). In contrast,
ICAM-1 expression on the surface of alveolar macro-
phages from patients with pneumonia was not elevated
(0.48 EU ± 0.35, p = not significant).
ICAM-1 expression on the surface of alveolar macro-
phages from healthy volunteers was augmented after
Stimulation with interferon-γ or TNF-α (fig. 1). In three
controls, a dose dependent increase of ICAM-1 ex-
pression was demonstrated (fig. 3). However patients'
alveolar macrophages did not respond to cytokines even
at high doses (500 kU/1 interferon-γ or 500 kU/1 TNF-















Fig. 2 Assay results given s A40s nm for the expression of ICAM-
1 on the surface of alveolar macrophages.





























Tumpur necrosis f ctor^a [kU/l]
Fig. 3 TNF-a ihduced ICAM-1 expression pn the surface of alve-
olar macrophages from healthy volunteers. Mean ± SD from 3
cases.
Irnmunocytochemical staining on cytocentrifuge prep-
arations correlated with the results obtained with the im-
m noenzymometric assay method. In pulmon ry s r-
coidosis the number of visibly stained cells was signifi-
cantly elevated when compared with healthy volunteers
(78% ± 11 vs. 40% ± 8 positive cells, p < 0.05). Fur^
thermore, we observed that staining of patients' alveolar
macrophages resulted in more intense colouring of the
cells than immunocytochemical staining of control al-
veolar macrophages (fig. 4).
Tumour necrosis factor-α bioassay
The black part of column 4 corresponds to the expression of the
ICAM-1 on the cell surface.
was determined in the supernatants of alveolar
macrophages. All sarcoid alveolar macrophages spon-
taneously released TNF-α, whereas only low TNF-a
concentration could be detected in the supernatants of
controls. TNF-α concentrations in patients ranged from
5-1375 kU/1 reflecting different stages of activity of
the disease. TNF-α concentration in the supernatants of
sarcoid alveolar macrophages correlated with the·
ICAM-1 surface expression of these cells (r s? 0.-77,
p < 0.05; 10). TNF-α was not determined in bacterial
pneumonia.
Discussion
We desoribe a method for the rapid, semi-a t m tic
identification of IC M-1 on the surface of alveolar mac-
rophages. Our results correlate with those obtained by
immunocytochemical staining, a technique which has
been used previously to esttoate surface expression of
adhesion molecules on lveot r macroplaages (8, 9). We
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Fig. 4 Immunocytochemical staining of cytospin preparations of
sarcoid alveolar macrophages (upper panel) and control alveolar
macrophages (lower panel) using alkaline phosphatase monoclonal
mouse anti-alkaline phosphatase complex (magnification: 400 X).
did not directly compare our ELISA with flow eytomet-
ric methods, which can also be used for detection of cell
surface markers. Flow cytometry is widely established
for lymphocyte typing and provides the advantage of
testing more than one antibody on identical cells. How-
ever alveolar macrophages show high background fluor-
escence, which interferes with the specific signal, es^
pecially when low receptor expression is expected (28).
In this fespect, we fouüd the immunoenzymometric as-
say to be very precise, allowing the quantification of
small differences in ICAM^l expression that are difficult
to assess by microscopic aiiälysis. The use of a micro-
plate reader for measuring the indicator enzyme activity
at the end of the experiment is not only convenient but
leads to more objective quantitative results than those
obtained by microscopic evaluation of cell stains. In ad-
dition, large numbers of cells can be analysed in one
experiment (e. g. investigation of 10 wells of a microtitre
plate equals the analysis of 10 X l O5 cells), which leads
to highly reproducible results.
Furthermore, differences in the colour intensity of the
immunocytochemically stained cells are not quantifiable
by microscopic evaluation. We observed marked Vari-
ation in this respect between patient samples and con-
trols, which may reflect up-regulation of the number of
binding sites expressed per cell (1).
Finally, the immunoenzymometric assay provides a set-
ting suitable for studying inodulatory effects of cyto-
kines or other agents on the expression of ICAM-1 on
the surface of alveolar macrophages in vitro. In sum-
mary we see this method äs an approach to a better
semi-quantitative identification of adhesion molecules
on the surface of alveolar raacrophages, compared with
conventional immunocytochemical staining.
The main finding of the clinical part of this study was
that ICAM-1 expression on the surface of alveolar mac-
rophages is differently regulated in patients with sar-
coidosis (mononuclear cell alveolitis) and bacterial
pneumonia (neutrophil alveolitis). Sarcoid alveolar mac-
rophages expressed significantly higher amounts of
ICAM-1 than macrophages of healthy volunteers. Our
data are consistent with recent work demonstrating in-
creased expression of ICAM-1 on the surface of alveolar
macrophages from patients with pulmonary sarcoidosis
using immunocytochemical staining (8, 9). We fiirther
demonstrated that ICAM-1 expression of control al-
veolar macrophages can be significantly increased by
Stimulation with either TNF- or interferon- . It has
been demonstrated previously that ICAM-1 expression
can be induced by cytokines on various cell types (1),
but no data were hitherto available on the in vitro induc-
tion of ICAM-1 on the surface of alveolar macrophages.
In contrast, ICAM-1 expression on the surface of al-
veolar macrophages from patients with bacterial pneu-
monia was not elevated, proving that upregulated
ICAM-1 expression is not an unspecific finding in pul-
monary inflammation. In the light of present knowledge,
ICAM-1 expression on the alveolar macrophages sur-
face seems to be crucial in the pathogenesis of lympho-
cyte accumulation and activation in the pulmonary com-
partment (10, 29). In neutrophil alveolitis different
mechanisms of bronchoalveolar cell activation are likely
to be involved.
Since alveolar macrophages can be harvested in large
numbers from sites of disease activity by bronchoalveo-
lar lavage, rapid and reliable identification of adhesion
molecules such äs ICAM-1 on the surface of cells from
the pulmonary compartment might be a useful tool for
further elucidation of the pathogenesis of these diseases.
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